The drug, called enzalutamide, is a pill that tackles prostate tumors from several different directions, interfering with molecular pathways that help them grow.Men taking enzalutamide lived 37 percent longer on average. The drug, made by a biotechnology company called Medivation is likely to be approved by the Food and Drug Administration within a few months and will cost about $6,000 a month.With medivation there is hope that it could be even more effective if it’s just used in a smarter way.Many cases are treated with radiation or surgery before the cancer starts to spread.Doctors are trying it in men soon after the cancer spreads out of the prostate to the lymph nodes and toward the bones where it becomes life-threatening.The hope is such treatment could bring a far more profound extension of survival. That will not reduce costs, but it would be even more exciting.For now medivation, despite the caveats, represents a huge advance against the second biggest cancer killer of men.Prostate cancer kills kills more than 28,000 U.S. men a year. Many cases are treated with radiation or surgery before the cancer starts to spread.
Prostate cancer would effect the normal function of the male reproductive system by causing problems of urination caused when the gland, enlarged by cancer,which is in the uretha.Begins to block the urethra, the tube that carries urine through the penis. The blockage causes the bladder to retain urine, thus the frequent urge to urinate.The back-up urine in the bladder may become infected, causing burning, painful cloudy and sometimes bloody urination.